Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey-Reference-Cited by-同舟云学术

Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey

Published:2023-05-21 Issue:6 Volume:35 Page:563-569
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Bakırtaş Mehmet¹^ORCID,Dal Mehmet Sinan¹,Yiğenoğlu Tuğçe Nur¹,Giden Asli Odabası²,Serin Istemi³,Başcı Semih¹,Kalpakci Yasin⁴,Korkmaz Serdal⁵,Ekinci Omer⁶,Albayrak Murat⁷,Basturk Abdulkadir⁸,Ozatli Duzgun²,Dogu Mehmet Hilmi⁹,Hacıbekiroglu Tuba⁴,Çakar Merih Kızıl¹,Ulas Turgay¹⁰,Miskioglu Mine¹¹,Gulturk Emine¹²,Eser Bulent¹³,Altuntas Fevzi¹¹⁴

Affiliation:

1. Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, University of Health Sciences, Ankara, Turkey

2. Department of Hematology, Ondokuz Mayis University, Samsun, Turkey

3. Istanbul Training and Research Hospital, Department of Hematology, University of Health Sciences, Istanbul, Turkey

4. Department of Hematology, Sakarya University, Sakarya, Turkey

5. Kayseri City Training and Research Hospital, Department of Hematology & Apheresis Unit, University of Health Sciences, Kayseri, Turkey

6. Gazi Yasargil Training and Research Hospital, Department of Hematology, University of Health Sciences, Diyarbakir, Turkey

7. Diskapi Yildirim Beyazit Training and Research Hospital, Department of Hematology, University of Health Sciences, Ankara, Turkey

8. Medicana International Istanbul Hospital, Istanbul, Turkey

9. Liv Hospital Ulus, Department of Hematology, Istinye University, Istanbul, Turkey

10. School of Medicine, Department of Internal Medicine, Division of Hematology, Near East University, Nicosia, Cyprus

11. Department of Hematology, Celal Bayar University, Manisa, Turkey

12. Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Department of Hematology, University of Health Sciences, Istanbul, Turkey

13. Department of Hematology, Medical Park Antalya Hospital, Antalya, Turkey

14. School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara Yildirim Beyazit University, Ankara, Turkey

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2023.2208439

Reference30 articles.

1. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

2. Multiple myeloma

3. Global Burden of Multiple Myeloma

4. First‐line therapy with bendamustine/prednisone/bortezomib—A GMMG trial for non‐transplant eligible symptomatic multiple myeloma patients

5. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study;Cancer Medicine;2024-04-30

2. INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice;Future Oncology;2024-01-10

3. Dexamethasone/ixazomib/lenalidomide;Reactions Weekly;2023-10-28